Curie Oncology

Curie Oncology is a premium private oncology practice based in Singapore, specialising in complex, personalised cancer care and clinical research across Southeast Asia.

It runs several specialist clinics in the leading medical centres of Singapore — including Mount Elizabeth Novena, Mount Elizabeth Orchard, Gleneagles, and Farrer Park — along with regional centres in Malaysia (Kuala Lumpur) and the Philippines (Cebu).

It is led by a team of senior medical oncologists, haematologists and radiation oncologists. Its subspecialties focus heavily on gastrointestinal, hepatobiliary, gynaecological, breast, thoracic, and haematological (blood) cancers.

It emphasises personalised cancer treatment based on genomic signature analysis (for example Oncotype DX, HalioDx Immunoscore) to assess the risk of recurrence, alongside targeted therapy, immunotherapy and systemic chemotherapy.

It has an active clinical research arm (Curie Research) taking part in global clinical trials, and also provides remote second opinion consultations, continuity of care across borders, and international patient coordination.

Personalised targeting of specific molecular mutations using targeted therapies and immunotherapies approved by the US FDA.

Advanced diagnostics: Next-generation sequencing (NGS) of tumour tissue, liquid biopsy, and monitoring of minimal residual disease (MRD) at the molecular level.

Specialised chemotherapy: Outpatient chemotherapy infusion, antibiotic and blood transfusion support, together with intraoperative chemotherapy options such as HIPEC where indicated.

Recurrence risk stratification: Risk classification using genomic signatures such as OncotypeDX (breast cancer) and Immunoscore (colon cancer).

Cell therapy: Capability for autologous and allogeneic haematopoietic stem cell transplantation for blood-related conditions.